Literature DB >> 8484613

Effect of inhaled nitric oxide during group B streptococcal sepsis in piglets.

J I Berger1, R L Gibson, G J Redding, T A Standaert, W R Clarke, W E Truog.   

Abstract

Group B streptococcus (GBS), a common gram-positive pathogen, causes similar pathophysiologic changes in newborn humans and animals. Infusion of GBS into neonatal animals produces pulmonary hypertension and ventilation/perfusion (Va/Q) mismatch in both early-phase (< 1 h) and late-phase (2 to 6 h) responses. Contrary to early phase, late phase causes pulmonary vascular injury. Nitric oxide (NO) is an inhaled vasodilator whose effect on pulmonary hypertension and Va/Q matching during early and late phases of GBS sepsis is unclear. We hypothesized that inhaled NO (150 ppm) would: (1) reverse early-phase GBS-induced pulmonary hypertension; (2) demonstrate less effectiveness in reversing late-phase GBS-induced pulmonary hypertension because of vascular injury; (3) improve late-phase GBS-induced Va/Q mismatching. Anesthetized, mechanically ventilated piglets (n = 10; 14 +/- 4 days of age) received a 240-min infusion of GBS (1.5 x 10(9) CFU/kg/h). Piglets received 30 min of NO (Study) or N2 (Control) at 30 and 210 min of GBS infusion. We found that inhaled NO selectively reversed early- and late-phase GBS-induced pulmonary hypertension and that NO was equally as effective in each phase. Inhaled NO did not reverse Va/Q mismatching during late-phase GBS. We conclude that 4 h of GBS sepsis does not injure neonatal pulmonary vascular smooth muscle sufficiently to impair its response to inhaled NO.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484613     DOI: 10.1164/ajrccm/147.5.1080

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

1.  Mean airway pressure and response to inhaled nitric oxide in neonatal and pediatric patients.

Authors:  George M Hoffman; Leif D Nelin
Journal:  Lung       Date:  2005 Nov-Dec       Impact factor: 2.584

2.  Cytokine responses to group B streptococci induce nitric oxide production in respiratory epithelial cells.

Authors:  Kenneth J Goodrum; Jane Poulson-Dunlap
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 3.  The pharmacology of inhaled nitric oxide.

Authors:  A D Edwards
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-03       Impact factor: 5.747

4.  Inhaled nitric oxide improved the outcome of severe right ventricular failure caused by lipopolysaccharide administration.

Authors:  T Uchida; K Ichikawa; K Yokoyama; C Mitaka; H Toyooka; K Amaha
Journal:  Intensive Care Med       Date:  1996-11       Impact factor: 17.440

5.  Inhaled nitric oxide in combination with volume resuscitation refines a porcine model of endotoxic shock.

Authors:  N A Herity; J D Allen; B Silke; A A Adgey
Journal:  Ir J Med Sci       Date:  2001 Jul-Sep       Impact factor: 1.568

Review 6.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Inhaled nitric oxide in acute respiratory failure: dose-response curves.

Authors:  L Puybasset; J J Rouby; E Mourgeon; T E Stewart; P Cluzel; M Arthaud; P Poète; L Bodin; A M Korinek; P Viars
Journal:  Intensive Care Med       Date:  1994-05       Impact factor: 17.440

8.  Inhaled nitric oxide in acute respiratory distress syndrome with and without septic shock requiring norepinephrine administration: a dose-response study.

Authors: 
Journal:  Crit Care       Date:  1997       Impact factor: 9.097

9.  Organic mononitrites of 1,2-propanediol act as an effective NO-releasing vasodilator in pulmonary hypertension and exhibit no cross-tolerance with nitroglycerin in anesthetized pigs.

Authors:  Kristofer F Nilsson; Waldemar Goździk; Claes Frostell; Stanisław Zieliński; Marzena Zielińska; Kornel Ratajczak; Piotr Skrzypczak; Sylwia Rodziewicz; Johanna Albert; Lars E Gustafsson
Journal:  Drug Des Devel Ther       Date:  2018-03-29       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.